Founder, Chair, and CEO of Lysogene, In 2008 - 2009, she served as a Member of the Paediatric Committee at the European Medicines Agency. In 2008, she also served on the French Ethical Review Board at Ambroise Paré Hospital. Ms. Pignet-Aiach has been involved with several not-for-profit organizations engaged in advocacy and research in the field of rare diseases. She is a founding executive member of the International Rare Diseases Research Consortium. A graduate from the ESSEC Business School, she majored in Economics at the Institut d’Études Européennes of University Paris 8.
W@ events participation:
CEO at LYSOGENE
February 2009 - Present • Neuilly, FranceA Genetic Medicine Company for Neurodegenerative and Neurological Diseases - Scope: Lysosomal Storage Diseases, Fragile X Syndrome, Parkinson’s Disease Corporate Management & Governance Financing: Lead financial strategy since inception Raised > 100mn € since inception via equity, non dilutive funding Entered into strategic patnership with Sarepta Therapeutics (NSDQ: SRPT, 2018) Took the company public on Euronext (EUR: LYS, 2017) Lead Investors’ Relations with top tier institutions - such as OrbiMed, Sofinnova Partners, European Investment Bank, French Public Bank of Investment-, Family Office & Retail R&D Operations: Developed a gene therapy platform Sourced assets from leading academic centers (US, EU, Israël) Translated 5 programs from discovery to up to phase 3 clinical study (US, EU) Preclinical – Toxicology – Bio Manufacturing (AAV vectors) – Clinical – Regulatory Lead two clinical programs (US, EU) Phase 3 AAVrh10-hSGSH in Gene Therapy in Patients with Mucopolysaccharidosis Type III A (MPS IIIA or Sanfilippo Syndrome) (NCT03612869) A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis (NCT04273269)